cannabinoid cb2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis大麻素cb2受体强化肥胖相关炎症、胰岛素抵抗和肝脏脂肪变性.pdfVIP

Cannabinoid CB2 Receptor Potentiates Obesity- Associated Inflammation, Insulin Resistance and Hepatic Steatosis Vanessa Deveaux1,2., Thomas Cadoudal1,2., Yasukatsu Ichigotani1,2., Fatima Teixeira-Clerc 1,2, Alexandre Louvet1,2, Sylvie Manin1,2, Jeanne Tran-Van Nhieu1,2,4, Marie Pierre Belot1,2, Andreas 5 6 7 7 7 8,9,10 Zimmer , Patrick Even , Patrice D. Cani , Claude Knauf , Remy Burcelin , Adeline Bertola , Yannick Le Marchand-Brustel8,9,10, Philippe Gual8,9,10, Ariane Mallat1,2,3, Sophie Lotersztajn1,2,3* ´ ´ ´ ´ ´ 1 INSERM, U955, Creteil, France, 2 Universite Paris Est, Faculte de Medecine, Creteil, France, 3 AP-HP, Groupe Hospitalier Henri Mondor – Albert Chenevier, Service ´ ´ ´ ´ ´ d’Hepatologie et de Gastroenterologie, Creteil, France, 4 AP-HP, Groupe Hospitalier Henri Mondor – Albert Chenevier, Departement de Pathologie, Creteil, France, 5 Department of Molecular Psychiatry, University of Bonn, Bonn, Germany, 6 INRA, UMR914, AgroParisTech, Physiologie de la Nutrition et du Comportement Alimentaire, CNRH-IdF, Paris, France, 7 INSERM, U858, Toulouse, France, 8 INSERM, U895, Team 8, Nice, France, 9 University of Nice-Sophia-Antipolis, Faculty of Medicine, Nice, France, 10 Centre Hospitalier Universitaire of Nice, Digestive Center, Nice, France Abstract Background: Obesity-associated inflammation is of critical importance in the development of insulin resistance and non- alcoholic fatty liver disease. Since the cannabinoid receptor CB2 regulates innate immunity, the aim of the